CARDIFF ONCOLOGY, INC. Payments to Acquire Debt Securities, Available-for-sale
CARDIFF ONCOLOGY, INC. (CRDF) reported Payments to Acquire Debt Securities, Available-for-sale of $13.87 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-11
- CARDIFF ONCOLOGY, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $1.30M, a 93.48% decline year-over-year.
- CARDIFF ONCOLOGY, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $12.57M, a 64.90% decline year-over-year.
- CARDIFF ONCOLOGY, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $6.72M.
- CARDIFF ONCOLOGY, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $9.34M, a 58.75% decline year-over-year.
- CARDIFF ONCOLOGY, INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $71.86M, a 204.97% increase from fiscal 2024.
- CARDIFF ONCOLOGY, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $23.56M, a 66.38% decline from fiscal 2023.
- CARDIFF ONCOLOGY, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $70.08M, a 23.18% decline from fiscal 2022.
- CARDIFF ONCOLOGY, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $91.23M, a 47.68% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $13.87M 10-Q · filed 2026-08-11 | $20.59M derived: sum of 3 quarters · filed 2026-08-11 | $29.93M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $12.57M 10-Q · filed 2026-05-14 | $19.29M derived: sum of 2 quarters · filed 2026-05-14 | $28.63M derived: sum of 3 quarters · filed 2026-05-14 | $48.62M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $6.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $16.06M derived: sum of 2 quarters · filed 2026-02-24 | $36.05M derived: sum of 3 quarters · filed 2026-08-11 | $71.86M 10-K · filed 2026-02-24 |
| 2025-09-30 | $9.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $29.33M derived: sum of 2 quarters · filed 2026-08-11 | $65.14M 10-Q · filed 2025-11-06 | $65.14M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $19.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $55.80M 10-Q · filed 2026-08-11 | $55.80M derived: sum of 3 quarters · filed 2026-08-11 | $78.44M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $35.81M 10-Q · filed 2026-05-14 | $35.81M derived: sum of 2 quarters · filed 2026-05-14 | $58.46M derived: sum of 3 quarters · filed 2026-05-14 | $58.46M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $22.64M derived: sum of 2 quarters · filed 2026-02-24 | $22.64M derived: sum of 3 quarters · filed 2026-02-24 | $23.56M 10-K · filed 2026-02-24 |
| 2024-09-30 | $22.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $22.64M derived: sum of 2 quarters · filed 2025-11-06 | $23.56M 10-Q · filed 2025-11-06 | $26.16M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | $919.00K 10-Q · filed 2025-07-29 | $3.51M derived: sum of 3 quarters · filed 2025-07-29 | $20.14M derived: sum of 4 quarters · filed 2025-07-29 |
| 2024-03-31 | $919.00K 10-Q · filed 2025-05-08 | $3.51M derived: sum of 2 quarters · filed 2025-05-08 | $20.14M derived: sum of 3 quarters · filed 2025-05-08 | $33.68M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $2.59M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $19.22M derived: sum of 2 quarters · filed 2025-02-27 | $32.76M derived: sum of 3 quarters · filed 2025-02-27 | $70.08M 10-K · filed 2025-02-27 |
| 2023-09-30 | $16.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $30.16M derived: sum of 2 quarters · filed 2024-11-07 | $67.49M 10-Q · filed 2024-11-07 | $78.30M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $13.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $50.87M 10-Q · filed 2024-08-08 | $61.67M derived: sum of 3 quarters · filed 2024-08-08 | $84.79M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $37.33M 10-Q · filed 2024-05-02 | $48.13M derived: sum of 2 quarters · filed 2024-05-02 | $71.25M derived: sum of 3 quarters · filed 2024-05-02 | $91.79M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $10.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $33.92M derived: sum of 2 quarters · filed 2024-02-29 | $54.46M derived: sum of 3 quarters · filed 2024-02-29 | $91.23M 10-K · filed 2024-02-29 |
| 2022-09-30 | $23.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $43.66M derived: sum of 2 quarters · filed 2023-11-02 | $80.43M 10-Q · filed 2023-11-02 | $108.18M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $20.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $57.31M 10-Q · filed 2023-08-09 | $85.06M derived: sum of 3 quarters · filed 2023-08-09 | $89.75M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $36.77M 10-Q · filed 2023-05-04 | $64.53M derived: sum of 2 quarters · filed 2023-05-04 | $69.21M derived: sum of 3 quarters · filed 2023-05-04 | $96.96M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $27.75M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $32.44M derived: sum of 2 quarters · filed 2023-03-02 | $60.19M derived: sum of 3 quarters · filed 2023-03-02 | $174.38M 10-K · filed 2023-03-02 |
| 2021-09-30 | $4.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $32.44M derived: sum of 2 quarters · filed 2022-11-03 | $146.63M 10-Q · filed 2022-11-03 | $146.63M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $27.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $141.95M 10-Q · filed 2022-08-04 | $141.95M derived: sum of 3 quarters · filed 2022-08-04 | $141.95M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $114.19M 10-Q · filed 2022-05-05 | $114.19M derived: sum of 2 quarters · filed 2022-05-05 | $114.19M derived: sum of 3 quarters · filed 2022-05-05 | $114.19M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $0.00 derived: sum of 2 quarters · filed 2022-02-24 | $0.00 derived: sum of 3 quarters · filed 2022-02-24 | $0.00 10-K · filed 2022-02-24 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $0.00 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |